Adam Quick
YOU?
Author Swipe
View article: Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis Open
Importance The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective To determine the effects …
View article: Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome
Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome Open
Importance Cryptogenic sensory peripheral neuropathy (CSPN) is highly prevalent and often disabling due to neuropathic pain. Metabolic syndrome and its components increase neuropathy risk. Diet and exercise have shown promise but are limit…
View article: Facial Onset Sensory and Motor Neuronopathy: A Case Series and Literature Review
Facial Onset Sensory and Motor Neuronopathy: A Case Series and Literature Review Open
Introduction: Facial Onset Sensory and Motor Neuronopathy (FOSMN) typically presents with paresthesias in the trigeminal nerve distribution and weakness that progresses rostro-caudally. Objective: To present two new cases of FOSMN, summari…
View article: Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial Open
Background Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS). Objective Determine whether PB/TURSO prolonged tracheostomy/ventilation…
View article: Contemporary Neuroscience Core Curriculum for Medical Schools
Contemporary Neuroscience Core Curriculum for Medical Schools Open
Medical students need to understand core neuroscience principles as a foundation for their required clinical experiences in neurology. In fact, they need a solid neuroscience foundation for their clinical experiences in all other medical d…
View article: The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016–2018: The Ohio Population-Based ALS Registry
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016–2018: The Ohio Population-Based ALS Registry Open
Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal, neuromuscular disease with no cure. ALS incidence rates have not been assessed specifically in Ohio, yet the state contains both metropolitan and rural areas with a variety of e…
View article: Long‐term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrate‐taurursodiol in <scp>amyotrophic lateral sclerosis</scp>
Long‐term survival of participants in the <span>CENTAUR</span> trial of sodium phenylbutyrate‐taurursodiol in <span>amyotrophic lateral sclerosis</span> Open
An orally administered, fixed‐dose coformulation of sodium phenylbutyrate‐taurursodiol (PB‐TURSO) significantly slowed functional decline in a randomized, placebo‐controlled, phase 2 trial in ALS (CENTAUR). Herein we report results of a lo…
View article: Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study
Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study Open
Most amyotrophic lateral sclerosis (ALS) cases are considered sporadic, without a known genetic basis, and environmental exposures are thought to play a causal role. To learn more about sporadic ALS etiology, we recruited n = 188 ALS patie…
View article: Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis Open
Sodium phenylbutyrate-taurursodiol resulted in slower functional decline than placebo as measured by the ALSFRS-R score over a period of 24 weeks. Secondary outcomes were not significantly different between the two groups. Longer and large…
View article: Variable reporting of <i>C9orf72</i> and a high rate of uncertain results in ALS genetic testing
Variable reporting of <i>C9orf72</i> and a high rate of uncertain results in ALS genetic testing Open
Ten years ago, commercial ALS genetic testing was limited to SOD1 sequencing. Commercial laboratories now offer a variety of multigene ALS panels, assays for the C9orf72 hexanucleotide expansion, and whole exome sequencing. The utility of …
View article: Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing
Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing Open
Background Amyotrophic lateral sclerosis ( ALS ) is increasingly recognized as a genetic disease. There is no consensus, however, as to the role of genetic testing in the care of the ALS patient. Methods We conducted a survey to study pati…
View article: Bedside direct observation of medical student-performed physical examination is highly rated in student satisfaction
Bedside direct observation of medical student-performed physical examination is highly rated in student satisfaction Open
This article was migrated. The article was marked as recommended. Objectives: To evaluate satisfaction among third year medical students with a bedside teaching exercise comprised of direct observation of student-performed physical examina…
View article: Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic Testing
Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic Testing Open
Although genetic testing for amyotrophic lateral sclerosis (ALS) is widely available, it is unknown what proportion of patients with ALS have access to genetic counseling and testing, and patient attitudes towards ALS genetic testing have …